Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

Diabetic retinopathy (DR) is a condition causing vision loss in adults with diabetes, and diabetic macular edema (DME) is a major reason for this vision loss. Anti-VEGF therapy involves medicines that stop the growth of leaky blood vessels in the retina, helping protect vision. These medicines, like ranibizumab and aflibercept, are injected into the eye. However, not all patients respond well to this treatment. This study will look at how dyslipidemia—an imbalance of fats like cholesterol in the blood—affects the success of anti-VEGF therapy in patients with DME. Dyslipidemia can be influenced by diet, smoking, or genetics. Higher cholesterol levels might be linked to DME complications, so understanding this relationship could improve treatment plans.

• Duration: Multiple visits for injections and check-ups.
• Compensation: Not specified in details.
• Risks: Potential poor response to treatment; exclusion if previous eye treatments.

Eligible participants are those with type II diabetes and specific eye measurements, but past eye treatments or certain eye conditions might exclude you.